Sandbox carlos: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 6: | Line 6: | ||
:* 2. '''Cystoisospora belli prophylaxis''' | |||
:* 2. '''Cystoisospora belli prophylaxis'''<ref>{{cite web | title = Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents | url = https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf }}</ref> | |||
::* 2.1 '''Primary prophylaxis''' | ::* 2.1 '''Primary prophylaxis''' | ||
:::* Insufficient evidence is available to support a general recommendation for primary prophylaxis for Cystoisosporiasis per se, especially for U.S. travelers in isoporiasis-endemic areas. | :::* Insufficient evidence is available to support a general recommendation for primary prophylaxis for Cystoisosporiasis per se, especially for U.S. travelers in isoporiasis-endemic areas. | ||
::* 2.2 '''Secondary prophylaxis (preventing recurrence in patients with CD4 count < 200 cells/mm<sup>3</sup>)''' | ::* 2.2 '''Secondary prophylaxis (preventing recurrence in patients with CD4 count < 200 cells/mm<sup>3</sup>)''' | ||
:::* Prefered regimen: [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO 3 times weekly | :::* Prefered regimen: [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO 3 times weekly | ||
| Line 31: | Line 34: | ||
:*'''HIV''' | :*'''HIV''' | ||
::*'''1. Patients with CD4 Count <200/mm3 (chronic treatment)''' | ::*'''1. Patients with CD4 Count <200/mm3 (chronic treatment)''' | ||
:::* Prefered regimen: [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO 3 times weekly | :::* Prefered regimen: [[Trimethoprim-sulfamethoxazole]] 160 mg/800 mg PO 3 times weekly | ||
Revision as of 18:00, 16 July 2015
- Cystoisospora belli
Return to Top
- 1. Cystoisospora belli treatment
- 2. Cystoisospora belli prophylaxis[1]
- 2.1 Primary prophylaxis
- Insufficient evidence is available to support a general recommendation for primary prophylaxis for Cystoisosporiasis per se, especially for U.S. travelers in isoporiasis-endemic areas.
- 2.2 Secondary prophylaxis (preventing recurrence in patients with CD4 count < 200 cells/mm3)
- Prefered regimen: Trimethoprim-sulfamethoxazole 160 mg/800 mg PO 3 times weekly
- Alternative regimen (1): Trimethoprim-sulfamethoxazole 160 mg/800 mg PO qd
- Alternative regimen (2): Trimethoprim-sulfamethoxazole 320 mg/1600 mg PO 3 times weekly
- Alternative regimen (3): Pyrimethamine 25 mg PO qd AND Leucovorin 5–10 mg PO qd
- Alternative regimen (4): Ciprofloxacin 500 mg PO 3 times weekly
- Note (1): Criteria for discontinuation of chronic maintenance therapy: sustained increase in CD4 count > 200 cells/mm3 for > 6 months in response to ART and without evidence of active Cystoisospora belli infection
- Note (2): Because of concerns about possible teratogenicity associated with first-trimester drug exposure, clinicians may withhold secondary prophylaxis during the first trimester and treat only symptomatic infection.
- Immunocompetent
- Prefered regimen: Trimethoprim-sulfamethoxazole 160 mg/800 mg PO OR IV qid for 10 days
- 1. Patients with sulfa intolerance
- Alternative regimen (1): Pyrimethamine 50-75 mg PO daily AND Leucovorin 10–25 mg PO daily
- Alternative regimen (2): Ciprofloxacin 500 mg PO BID for 7 days
- HIV
- 1. Patients with CD4 Count <200/mm3 (chronic treatment)
- Prefered regimen: Trimethoprim-sulfamethoxazole 160 mg/800 mg PO 3 times weekly
- Alternative regimen (1): Trimethoprim-sulfamethoxazole 320 mg/1600 mg PO 3 times weekly
- Alternative regimen (2): Pyrimethamine 25 mg PO daily AND Leucovorin 5–10 mg PO daily
- Alternative regimen (3): Ciprofloxacin 500 mg PO 3 times weekly